fool.com · 27 jun

Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean

This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.

fool.com · 24 jun

Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?

Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026. This sale represented 38.5% of Agarwal's direct holdings, reducing direct ownership from 26,696 to 16,406 shares.

zacks.com · 12 jun

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com · 10 jun

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

fool.com · 31 may

An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million

This clinical-stage biotech focused on antibody therapies for immunological disorders reported a notable insider sale in its latest filing.

globenewswire.com · 28 may

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026.

globenewswire.com · 13 may

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026

fool.com · 13 may

Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally

This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.